🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

PEN PEN

Company Profile ↓
$323.21
+34.45% 1Y
Mkt Cap$12.68B
P/E71.51
P/B8.88
52W High$359.40
52W Low$225.54
Book Value$36.39
EPS (TTM)$4.52

Company Overview

PEN (PEN) is a publicly traded company listed on with a market capitalization of $12.68B. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.

Why Investors Should Care

Consistent Profit Growth

Net profit has compounded at 40.9% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 28.5% CAGR over the past five years.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.15.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Dec 2025 Revenue of $1.40B (+17.5% YoY); net profit $177.69M.
  • Trailing 12 Months Year-on-year growth — revenue +17.5%, earnings +1168.1%.
  • 5-Year Trend Long-term compounding — revenue CAGR 28.5%, profit CAGR 40.9%.

Growth & Price Performance

Compounded Sales Growth

5 Years:28.52%
1 Year:17.50%

Compounded Profit Growth

5 Years:40.87%
1 Year:1,168.11%

Stock Price Performance

1 Year:+34.45%
6 Months:-9.21%
3 Months:-0.20%
1 Month:+1.54%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 73% of range
$225.54 $359.40
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)63.33 · Neutral
Price Performance
1M+1.54%
3M-0.20%
6M-9.21%
1Y+34.45%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 28.5% over 5 years.
  • Profit CAGR of 40.9% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Trading at a high P/E of 71.5.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
71.51
Industry PE
-
Forward P/E est.
35.76
PEG Ratio
-
Book Value
$36.39
Price to Book
8.88
P/S
-
EV/EBITDA
-
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
28.52%
Profit 5Y
40.87%
Revenue (YoY)
17.50%
Earnings (YoY)
1,168.11%

Profitability & Returns

ROCE
11.52%
ROE
12.45%
ROA
9.73%
Profit Margin
12.66%
Op Margin
13.48%
Gross Margin
67.14%
EPS (Latest Qtr)
$0.88
EPS (TTM)
$4.52

Balance Sheet & Liquidity

Debt/Equity
0.15
Quick Ratio
4.29
Current Ratio
6.64
Debt
$219.70M
Total Assets
$1.97B
Current Assets
$1.34B
Working Capital
$1.03B

Ownership

Promoter Holding
2.89%
Chg in Prom Hold
0.00%
FII / Inst Holding
86.88%
Chg in FII Hold
0.00%

Financial Snapshot

Enterprise Value
-
Total Revenue (TTM)
$1.40B
EBITDA
$223.91M
Free Cash Flow
$174.93M
Operating Cash Flow
$238.66M
Shares Outstanding
39.23M
Gross Margin
67.14%
Payout Ratio
-
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue --73.21M80.59M83.91M-102.70M109.64M111.81M-128.44M134.20M139.50M-137.33M105.11M151.08M-169.20M184.26M190.12M-203.90M208.34M213.68M-241.40M261.50M270.95M-278.65M299.40M301.04M-324.14M339.45M354.69M385.38M374.76M390.05M
Cost of Revenue -----------------------------------115.44M114.27M123.26M121.35M125.10M
Gross Profit 42.87M46.58M47.71M50.93M54.78M63.73M66.56M72.25M75.01M78.71M83.91M93.93M96.00M98.13M88.01M64.93M90.92M94.31M111.34M118.69M119.91M125.45M127.42M134.03M135.33M138.43M151.07M166.86M177.72M186.99M181.14M162.83M200.31M-215.88M224.01M240.42M262.13M253.41M264.94M
Operating Expenses -----------------------------------183.18M191.58M202.90M215.18M223.91M
Operating Income -1.36M--2.05M-1.33M683.00K-4.04M9.28M-20.85M-11.15M12.80M12.98M-610.00K-17.65M-20.16M-13.46M10.31M8.78M--4.05M-139.00K5.43M-8.01M17.89M12.62M-12.10M-80.96M35.36M-40.35M40.83M48.84M59.23M38.23M41.04M
EBITDA -----------------------------------51.14M55.15M68.43M46.58M52.11M
Interest Expense -----------------------------------319.00K338.00K333.00K317.00K311.00K
Pretax Income -----------------------------------45.31M52.33M63.63M41.69M46.19M
Tax Provision -----------------------------------40.00K6.47M16.29M9.10M11.38M
Net Income 11.91M-2.40M-3.11M-1.56M238.00K9.08M5.49M13.38M-18.93M6.66M10.70M16.59M11.48M9.69M1.43M-11.96M-8.81M3.65M11.84M9.23M8.85M-24.63M79.00K-3.69M-2.27M3.88M8.56M18.96M9.21M54.22M11.00M-60.20M29.53M-39.22M45.27M45.85M47.34M32.58M34.81M
Diluted EPS 0.35-0.08-0.10-0.050.010.250.150.37-0.550.180.300.460.320.270.04-0.34-0.240.100.320.250.24-0.660.00-0.10-0.060.100.220.480.231.380.28-1.550.75-1.001.151.171.200.820.88
R&D Expense 6.50M-7.03M8.09M8.13M-8.01M8.19M9.09M-11.67M13.46M13.73M-12.95M22.73M34.92M-18.08M17.74M16.73M-20.56M19.56M21.32M-19.99M21.54M------------

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 88.85M125.51M186.09M263.32M333.76M444.94M547.40M560.41M-847.13M1.06B1.19B1.40B
Cost of Revenue ---------311.93M375.88M439.62M461.23M
Gross Profit 57.88M82.84M124.06M170.83M217.14M292.53M371.96M338.18M-535.21M682.64M755.00M942.44M
Operating Expenses ---------529.12M590.88M668.77M753.19M
Operating Income -1.13M3.01M4.18M-1.35M1.17M-852.00K47.51M-38.94M-6.08M91.77M86.22M189.25M
EBITDA ---------29.96M108.65M45.99M223.91M
Interest Expense ---------1.75M1.74M1.42M1.31M
Pretax Income ---------3.89M79.65M20.87M205.12M
Tax Provision ---------5.89M-11.30M6.86M27.44M
Net Income 4.10M2.25M2.37M14.81M4.66M6.60M48.46M-15.70M--2.00M90.95M14.01M177.69M
Diluted EPS 0.14-0.180.080.440.130.181.34-0.44--0.052.320.364.52
R&D Expense 14.08M15.57M18.03M23.88M31.66M36.16M-------

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2012Dec 2013Dec 2014Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Dec 2017Dec 2018Jan 2019Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --121.38M263.85M275.12M283.94M306.49M308.25M476.67M515.01M557.86M665.90M822.98M-1.37B1.56B1.53B1.83B
Current Assets --------------755.70M915.40M951.12M1.22B
Cash & Equivalents 7.43M4.13M3.29M19.55M---13.24M50.64M67.85M-72.78M69.67M-69.86M167.49M324.40M186.90M
Inventory --------------334.01M388.02M406.74M431.55M
Receivables --------------203.38M201.77M167.67M190.02M
Total Liabilities --22.28M31.33M37.07M36.39M42.88M41.71M76.26M92.59M135.44M180.29M185.19M-372.03M377.36M382.25M398.92M
Current Liabilities --20.82M28.15M---35.80M51.58M66.06M69.54M91.05M105.93M-144.93M151.14M158.34M183.13M
Long Term Debt ------------------
Total Debt --------------235.77M234.34M223.39M219.70M
Total Equity -12.75M-8.06M-12.37M232.52M238.05M247.56M263.60M266.55M400.41M422.24M-485.89M641.50M-998.86M1.18B1.15B1.43B
Shares Outstanding --------------38.11M38.68M38.49M39.23M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -3.40M-6.39M-20.69M-12.81M12.69M28.81M26.65M-33.24M--55.66M97.33M168.48M238.66M
Investing Cash Flow -1.25M-37.00M-85.82M687.00K-77.65M-385.00K-12.71M-104.15M-54.79M-16.08M77.62M-404.59M
Financing Cash Flow 2.18M42.90M122.83M7.13M104.36M-9.81M-8.96M134.92M-11.62M16.20M-87.01M26.53M
Capital Expenditure -798.00K-3.89M-5.47M-13.63M-12.53M-9.60M-22.11M-24.76M--19.30M-15.21M-21.18M-63.73M
Free Cash Flow -4.19M-10.28M-26.16M-26.44M159.00K19.20M4.54M-58.00M--74.96M82.12M147.30M174.93M
Net Change in Cash ---------10.75M97.46M159.10M-139.40M
Share Buybacks ---------00100.39M0

Ratios (Annual)

Figures in %.

Metric Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % 65.1%66.0%66.7%64.9%65.1%65.7%68.0%60.3%-63.2%64.5%63.2%67.1%
Operating Margin % -1.3%2.4%2.2%-0.5%0.3%-0.2%8.7%-6.9%-0.7%8.7%7.2%13.5%
Net Margin % 4.6%1.8%1.3%5.6%1.4%1.5%8.9%-2.8%--0.2%8.6%1.2%12.7%
ROE % -50.8%-18.1%1.0%5.6%1.2%1.6%10.0%-2.4%--0.2%7.7%1.2%12.4%
ROCE % -3.0%1.8%-0.5%0.3%-0.2%8.3%-5.4%-0.5%6.5%6.3%11.5%

Shareholding Pattern

Insiders
2.89%
Institutions
86.88%
Public Float
89.47%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for PEN

Yahoo Finance hu, 30 Jul 2026

Penumbra, Inc. Reports Second Quarter 2026 Financial Results

Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the second quarter ended June 30, 2026.

Yahoo Finance Sun, 26 Jul 2026

Penumbra (PEN) Following THUNDERBOLT Debut, Is The Stock A Bargain Or Fairly Valued

Penumbra (PEN) is back in focus after Novant Health reported successful use of its newly cleared THUNDERBOLT computer assisted vacuum thrombectomy system at a North Carolina comprehensive stroke center. See our latest analysis for Penumbra.…

Yahoo Finance Sat, 25 Jul 2026

Penumbra (PEN) Wins FDA Clearance For THUNDERBOLT After Strong Stroke Study

Penumbra (NYSE:PEN) received FDA clearance for its THUNDERBOLT computer-assisted vacuum thrombectomy system for acute ischemic stroke treatment. The THUNDER study reported strong safety and efficacy results for THUNDERBOLT in stroke care. A…

Yahoo Finance Fri, 24 Jul 2026

Magnendo Secures $18M Series A Financing to Transform Endovascular Access for Stroke Intervention

MIT spinout to accelerate product development and first-in-human studies of its magnetic robotic navigation platform designed to dramatically improve the speed and reliability of neuro-endovascular procedures NEWTON, Mass., July 24, 2026 (G…

Yahoo Finance Wed, 22 Jul 2026

THUNDER Study Demonstrates Penumbra's THUNDERBOLT is Safe and Effective for Stroke Care

Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced the results of THUNDER, an Investigational Device Exemption (IDE) study, to evaluate the safety and effectiveness of THUNDERBOLT™, the company's novel computer …

Yahoo Finance Mon, 20 Jul 2026

3 Medical Device Stocks Giving Investors a Different Healthcare Play

Globus Medical, Inspire Medical Systems, and Penumbra show varied revenue growth and analyst ratings, offering medical device investors alternatives to traditional pharmaceutical stocks.

PEN — Frequently Asked Questions

What is the current share price of PEN?

As of 2026-08-05 17:25 PDT, PEN trades at $323.21 on NASDAQ/NYSE. Its 52-week range is $225.54 to $359.40.

What is the market capitalisation of PEN?

PEN has a market capitalisation of $12.68B on NASDAQ/NYSE.

What is the P/E ratio of PEN?

PEN trades at a trailing price-to-earnings (P/E) ratio of 71.51. Its price-to-book (P/B) ratio is 8.88.

What is the return on equity (ROE) of PEN?

PEN has a return on equity (ROE) of 12.45%. Its return on capital employed (ROCE) is 11.52%.

Is PEN a good stock to buy?

This page provides a data-driven analysis of PEN, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space